A subtype of patients with AD may have a predominantly allergic phenotype of conjunctivitis and, thus, the therapeutic effects of IL-4Rα blockade we observed in our preclinical model could reflect this disease phenotype. This evidence concerns the gene IL4R and conjunctivitis.